Close

Akari Therapeutcis (AKTX) Reports Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC

September 27, 2018 6:55 AM EDT Send to a Friend
Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login